Every month there’s more happening in myopia management than any one clinician can keep up with — new studies, new products, new debates. That’s exactly why we built this series.
In this episode, I sit down with two practitioners who’ve been in the trenches of myopia management: Dr. Andrew Brauer of Eye Care Center of DuPage and Dr. Cary Herzberg, with 40+ years of myopia management experience. We go through the five most important stories from Q1 2026 — and we don’t hold back on the disagreements.
🎙️ Full episode + subscriber bonus: https://myopiamindset.substack.com 📧 Subscribe for weekly episodes, articles, and exclusive bonus content
In this episode:
LAMP Study (8-year follow-up): The data is in — tapering atropine before stopping leads to less rebound than abrupt cessation. But is a quarter-diopter reduction enough to change how you manage discontinuation? And should we even be framing myopia management as something that ends? | Eight-Year Results of the LAMP Randomized Clinical Trial
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2846905
Essilor Stellest 2.0: More plus, potentially twice the efficacy of the original. Andrew raises the concern nobody wants to say out loud about spectacle-only practices. | Next-Generation Spectacle Lens Aims to Strengthen Myopia Control in Children
https://theophthalmologist.com/issues/2026/articles/march/next-generation-spectacle-lens-aims-to-strengthen-myopia-control-in-children/
Contrast Theory of Myopia: Dr. Ashley Tucker’s piece in Review of Myopia Management ties color vision research to myopic defocus. Is this a new mechanism — or just a new way of describing the one we already know? | When Color Vision Research Meets Myopia Control
https://reviewofmm.com/when-color-vision-research-meets-myopia-control/
Sight Glass DOT Lenses at NCC 2026: New data, 20% African American representation in the study, and the astigmatism question finally answered. | SightGlass Vision Presents Latest Findings on DOT Spectacles at NCC 2026
https://reviewofmm.com/sightglass-vision-presents-latest-findings-on-dot-spectacles-at-ncc-2026/
European Delphi Consensus: Should myopia be classified as a progressive disease? Some colleagues still push back. Andrew and Cary explain why it’s not a question worth arguing. | Consensus on Evidence Gaps and Unmet Needs in Childhood Myopia
https://reviewofmm.com/consensus-on-evidence-gaps-and-unmet-needs-in-childhood-myopia/
Whether you’re deep into myopia management or just building your program, this panel is your monthly check-in.
🎧 Listen now — and if you’re a paid subscriber, stay tuned for the bonus segment coming later this week. https://myopiamindset.substack.com
The Myopia Mindset is a weekly podcast for optometrists, ophthalmologists, and eyecare professionals devoted to myopia management. New episodes every week.
